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Background: This paper describes a Phase 1, single-center, randomized, open-label, two-period 
crossover study which compared the pharmacodynamic effects of single doses of dexlansoprazole 
modified-release 60 mg and esomeprazole 40 mg on 24-hour intragastric pH in healthy adult 
subjects.
Methods: Forty-four subjects aged 20–54 years were randomized in a 1:1 ratio to two 
sequence groups defining the order in which they received dexlansoprazole and esomeprazole in 
periods 1 and 2. Primary pharmacodynamic end points over 24 hours postdose were percentage 
of time with intragastric pH . 4 and mean pH, and secondary pharmacodynamic end points 
were percentage of time intragastric pH . 4, and mean pH at 0–12 hours, and at .12–24 hours 
postdose. Each drug was given after an overnight fast and one hour before breakfast. Continuous 
pH recording began immediately before dosing through to 24 hours postdose.
Results: At 0–24 hours postdose, the mean percentage of time with pH . 4 for dexlansoprazole 
and esomeprazole was 58% and 48%, respectively; the difference was statistically significant 
(P = 0.003). The average of mean pH values at 0–24 hours postdose for dexlansoprazole 
and esomeprazole were 4.3 and 3.7, respectively; the difference was statistically significant 
(P , 0.001). At .12–24 hours postdose, mean percentage of time with pH . 4 and average 
of mean pH were greater for dexlansoprazole (60% and 4.5, respectively) compared with 
esomeprazole (42% and 3.5, respectively); the difference was statistically significant (P , 0.001 
for both intervals). At 0–12 hours postdose, the difference in dexlansoprazole and esomeprazole 
values for the pharmacodynamic end points was not statistically significant.
Conclusion: For the entire 24-hour postdose period, predominantly resulting from the 
.12–24-hour postdose interval, the average intragastric pH following a single dose of 
dexlansoprazole 60 mg was higher compared with that observed following a single dose of 
esomeprazole 40 mg, and the difference was statistically significant.
Keywords: proton pump inhibitor, TAK-390MR, esomeprazole, intragastric pH, single dose, 
pharmacokinetics
Introduction
Dexlansoprazole and esomeprazole belong to the class of drugs known as proton pump 
inhibitors. Proton pump inhibitors inhibit the secretion of hydrogen ions in the stomach 
by inhibiting the (H+,K+)-ATPase enzyme (proton pump) at the secretory surface of 
the gastric parietal cell, resulting in potent inhibition of gastric acid secretion with 
prolonged elevation of intragastric pH. Both drugs are marketed in the United States 
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for healing of and maintenance of healed erosive esophagitis 
and treatment of heartburn associated with symptomatic, 
nonerosive gastroesophageal reflux disease.
One of the limitations to the use of proton pump 
inhibitors on a once-daily basis has been incomplete 
acid   suppression over the 24-hour postdose interval.1 
  Dexlansoprazole modified-release is a formulation that 
uses an innovative dual delayed-release (DDR™) delivery 
system. DDR technology is designed to provide an initial 
drug release in the proximal small intestine followed by 
another drug release at more distal regions of the small 
intestine   several hours later.2 As a result, dexlansoprazole 
modified-release produces a plasma concentration-time 
profile with two   distinct peaks, whereby the first peak occurs 
1–2 hours after administration, followed by a   second peak 
at 4–5 hours postdose.2–4   Esomeprazole is a delayed-release 
formulation with single-release characteristics that produces 
maximum plasma concentrations at approximately 1.6 hours 
postdose.5   Dexlansoprazole modified-release may be taken 
without regard to meals.4,6 In comparison, esomeprazole is 
  recommended to be taken at least one hour before a meal to 
achieve maximal efficacy.5
The pharmacodynamic, pharmacokinetic, and safety 
profiles of various proton pump inhibitors following 
administration in humans have been extensively studied.2,3,7–11 
However, this is the first clinical study reported in the literature 
as a head-to-head comparison of the pharmacodynamics of 
dexlansoprazole modified-release and esomeprazole after 
a single dose. Because the study population consisted 
of healthy adult subjects, no efficacy endpoints were 
evaluated in this study. Comparison of the single-dose 
pharmacodynamics of dexlansoprazole modified-release and 
esomeprazole in a well controlled crossover study adds to the 
knowledge base for proton pump inhibitors without having 
to compare across studies. It is known from the literature 
that these two proton pump inhibitors have pharmacokinetic 
differences. Esomeprazole exhibits a dose-dependent 
and time-dependent pharmacokinetic profile that results 
in an approximate 2.5-fold increase in bioavailability at 
steady state and increased pharmacodynamic effects after 
five days of once-daily dosing.12 The pharmacokinetics of 
dexlansoprazole modified-release are time-independent and 
the pharmacokinetic and pharmacodynamic profiles after 
five days of once-daily dosing are similar (less than 10% 
difference) to those observed after a single dose.2,4
The objective of the current trial was to evaluate the 
pharmacodynamic effects of single doses of dexlansoprazole 
modified-release 60 mg and esomeprazole 40 mg on 24-hour 
intragastric pH in healthy subjects. The dosage strengths 
chosen for this study were the highest approved for healing 
of erosive esophagitis (60 mg for dexlansoprazole modified-
release and 40 mg for esomeprazole).
Materials and methods
Ethics
The  institutional  review  board  (IntegReview, 
Austin, TX) reviewed and approved the study protocol, 
protocol   amendment 1, and the informed consent form prior 
to   enrollment of   subjects; all subjects were enrolled under 
amendment 1. This study was conducted in accordance with 
the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use Good Clinical Practice, the ethical principles 
of the World Medical Association Declaration of Helsinki, 
and local regulations.
Study population
Eligible subjects were adult men or women, aged 18–55 
years inclusive, and in good health. Women of childbearing 
potential were required to have negative urine pregnancy 
tests at screening and at day -1 of period 1. Sexually active 
women and men agreed to use acceptable contraception for a 
period of time starting from signing of the informed consent 
throughout the duration of the study and for 30 days following 
the last dose of study drug.
Women who were pregnant or lactating, and any subjects 
with an uncontrolled, clinically significant disorder or 
abnormality which may have impacted the ability of a subject 
to participate in the study or potentially confound the study 
results were excluded as per the study exclusion criteria. In 
addition, subjects were excluded if they had a hypersensitivity 
to any component of dexlansoprazole modified-release, 
esomeprazole, or related compounds, had any significant 
findings from physical examination or clinical laboratory 
test results, had positive test results on urine screens for 
alcohol and drugs of abuse, a positive serum caffeine screen, 
a positive breath test for Helicobacter pylori at screening, 
or consumed any medication or foods contraindicated by 
the protocol.
Medication or dietary products including grapefruit or 
Seville oranges, nicotine-containing products, prescription 
medication (except for hormonal contraceptives and hormone 
replacement therapy, if on a stable dose for at least 90 days 
prior to day 1 of period 1), hepatic or renal clearance altering 
agents, over the counter medications, vitamin supplements, 
and alcohol or caffeine-containing products were excluded 
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during the screening and treatment periods. Occasional use 
of acetaminophen (#2 g/day) was allowed, except on day 1 
of each period.
Study design
This open-label, randomized, two-period crossover study 
was conducted at a single study site. During each period, 
subjects were confined to the study site from day -1 until 
all study procedures were completed on day 2. A washout 
interval of at least seven days separated doses of study 
drugs in periods 1 and 2. This washout interval was 
considered sufficient because the half-lives are 1–2 hours4 
and approximately 1.6 hours5 for dexlansoprazole and 
esomeprazole, respectively, and it allowed intragastric pH to 
return to baseline levels between doses of study drugs.
On day 1 of each period, study drug was administered at 
approximately 8 am after an overnight fast of at least eight 
hours and followed by a 60-minute postdose fast. Breakfast, 
lunch, dinner, and an evening snack were served at hours 1, 4, 9, 
and 12 postdose, respectively. During confinement in period 2, 
subjects received meals identical to those received by the 
confined subjects in period 1. Each meal was standardized to 
contain approximately 25% fat. Blood samples were collected 
at scheduled time points up to 24 hours postdose to quantify 
dexlansoprazole and esomeprazole plasma concentrations. 
Intragastric pH recording was performed for 24 hours 
beginning immediately prior to study drug administration on 
day 1 of each period. Subjects fasted overnight for at least 
eight hours prior to collection of blood and urine samples for 
safety laboratory tests on day 2 of each period.
Pharmacodynamic assessments
On day -1 of period 1, a single-channel antimony probe 
attached to a Digitrapper® data recorder (Sierra Scientific 
Instruments, Los Angeles, CA) was inserted intranasally 
into the stomach to a distance of approximately 10 cm past 
the lower esophageal sphincter. This procedure verified that 
the subject could tolerate probe insertion and obtained the 
length of the probe insertion that was used on day 1 of periods 
1 and 2. The unit for measurement of intragastric pH was 
calibrated with standard buffers (pH approximately 1 and 
7) before each use. On day 1 of periods 1 and 2, intragas-
tric pH was recorded every four seconds over the 24-hour 
postdose interval; however, median intragastric pH values 
over 15-minute intervals were determined and used for the 
calculation of pharmacodynamic parameters.
The primary pharmacodynamic parameters calculated 
for each treatment regimen over 24 hours postdose were 
percentage of time with intragastric pH . 4 (ie, percentage 
of time that the medians over 15-minute intervals had pH 
values . 4) and mean intragastric pH (ie, the average of the 
medians over 15-minute intervals). Secondary pharmaco-
dynamic parameters were percentage of time with pH . 4 
and mean intragastric pH calculated for the time intervals 
0–12 hours postdose and .12–24 hours postdose.
Pharmacokinetic assessments
Blood samples for the determination of dexlansoprazole and 
esomeprazole concentrations in plasma were collected into 
chilled Vacutainers® containing dipotassium ethylenediamine-
tetraacetic acid (K2EDTA) according to the following 
schedule: baseline (within 30 minutes prior to day 1 dosing) 
and at hours 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, and 
24 postdose. Plasma concentrations of dexlansoprazole and 
esomeprazole were determined by liquid chromatography 
and tandem mass spectrometry at PPD Development 
(Middleton, WI), with validated concentration ranges of 
2.00–2000 ng/mL for dexlansoprazole and 1.00–1000 ng/mL 
for esomeprazole. Plasma concentrations below the lower 
limit of quantification were set to zero for calculation of mean 
plasma concentrations and derivation of individual subject 
pharmacokinetic parameters.
The following pharmacokinetic parameters were 
calculated for dexlansoprazole and esomeprazole plasma 
concentration data: area under the plasma concentration-
time curve from time 0 to the time of the last quantifiable 
concentration (AUCt) and to infinity (AUC∞); maximum 
observed plasma concentration (Cmax); time to reach Cmax 
(Tmax); elimination half-life; oral clearance; and apparent 
volume of distribution. Pharmacokinetic parameters 
were derived using noncompartmental methods with 
WinNonlin® Enterprise, Version 5.2 (Pharsight Corporation, 
Mountain View, CA). Actual sample times, rather than 
scheduled sampling times, were used in all pharmacokinetic 
computations involving sampling times.
Assessment of CYP2C19 metabolizer 
status
The cytochrome P450 (CYP) 2C19 isozyme is a polymorphic 
enzyme that is involved in the metabolism of dexlanso-
prazole4 and esomeprazole.5 One blood sample for DNA 
isolation was collected before dosing on day 1 of period 1 
from each subject in the study into plastic K2EDTA spray-
coated tubes and stored under frozen conditions. A portion 
of the DNA sample was analyzed for the presence of 
CYP2C19 allelic variants (Covance Central Laboratory, 
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Indianapolis, IN). Genotyping and phenotyping analysis 
for CYP2C19 was performed for all subjects to determine 
CYP2C19   metabolizer status.
Statistical analysis
A sample size of 44 subjects, 22 subjects per sequence group, 
allowed for up to four dropouts (an approximate 9% dropout 
rate) and still provided at least 93% power to detect a 10% 
difference in the percentage of time with intragastric pH . 4 
over 24 hours between the two treatment regimens. The 
sample size was calculated using 159.13 as the intrasubject 
variance for the percentage of time with intragastric pH . 4, 
which was estimated from a previous dexlansoprazole 
modified-release study.6 The power for detecting a differ-
ence of 0.5 in mean 24-hour pH between the two treatment 
regimens was expected to be greater than 95%. Differences 
were deemed statistically significant if P was #0.05.
An analysis of variance model that included fixed 
effects of sequence, period, and regimen, as well as a 
random effect of subject nested within sequence was fitted 
to the pharmacodynamic parameters. Pairwise comparisons 
between treatment regimens were conducted. Intragastric 
pH values . 0 but #8 were included in the median 
calculations. Only subjects who had valid pharmacodynamic 
parameters estimated for both periods were included in the 
pharmacodynamic analyses for that parameter. The effect 
of CYP2C19 metabolizer status on the pharmacodynamics 
of dexlansoprazole and esomeprazole was assessed by 
performing an additional analysis of variance that excluded 
the subjects identified as CYP2C19 poor metabolizers.
Descriptive statistics were used to summarize the plasma 
concentrations of dexlansoprazole and esomeprazole and 
their single-dose pharmacokinetic parameters from time 
of dose (0 hour) to 24 hours postdose for all subjects who 
completed at least one treatment period.
All data analyses were performed using SAS® Version 9.1 
(SAS Institute, Cary, NC). There was no imputation of 
incomplete or missing data.
Safety analysis
All subjects who received at least one dose of study drug 
were included in the safety analysis. All safety assessments, 
including adverse events, clinical laboratory evaluations, 
12-lead electrocardiogram results, vital sign measurements, 
and physical examination findings were summarized by 
treatment regimen with descriptive statistics, where deemed 
appropriate. A treatment-emergent adverse event was defined 
as an adverse event or serious adverse event that started or 
worsened after receiving the first dose of study drug and 
within 30 days after the last dose of study drug. Adverse event 
verbatim reported terms were coded to system organ class 
and then to the first listed preferred term using the Medical 
Dictionary for Regulatory Activities, Version 13.1.
Results
Study population
This study was conducted between September 2010 
and October 2010. Forty-four subjects, comprising 
21 (47.7%) men and 23 (52.3%) women were enrolled, of 
whom 43 completed the study in accordance with the protocol 
and had complete pharmacodynamic and pharmacokinetic 
data for both treatment periods. Ten of the 44 subjects 
(22.7%) were black or African American, while the race 
of the remaining 34 subjects (77.3%) was Caucasian. The 
mean age was 36.7 (range 20–54) years, weight 73.1 kg, 
height 170.4 cm, and body mass index 25.1 kg/m2. One 
subject voluntarily withdrew consent for personal reasons 
after receiving esomeprazole in period 1, but prior to 
administration of dexlansoprazole modified-release in 
period 2. Pharmacokinetic and safety data for this subject 
from period 1 were included in the summaries. However, 
because the analysis of variance required pharmacodynamic 
data from both treatment regimens, this subject was not 
included in the pharmacodynamic analysis. Forty-two of 
44 subjects (95.5%) were extensive CYP2C19 metabolizers 
and two subjects (4.5%) were poor CYP2C19 metabolizers. 
Data from all subjects, regardless of CYP2C19 metabolizer 
status, were included in the pharmacodynamic analyses and 
pharmacokinetic summary because this was a crossover 
study where subjects received both treatment regimens and 
the subjects acted as their own control.
Pharmacodynamics
Mean intragastric pH over 24 hours after single doses of 
dexlansoprazole modified-release and esomeprazole are pre-
sented in Figure 1. Period and sequence effects were not found 
to be statistically significant. The pharmacodynamic profiles 
at 0–24 hours after a single dose of dexlansoprazole modi-
fied-release or esomeprazole were generally similar to that 
reported in the literature.2,3,9,10,12
Over the 24-hour postdose period, the mean percentage of 
time with intragastric pH . 4 was 58% for dexlansoprazole 
compared with 48% for esomeprazole; the difference was 
statistically significant (P = 0.003, Figure 2). Similarly, 
.12–24 hours postdose, the mean percentage of time 
with intragastric pH . 4 was 60% for dexlansoprazole 
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relative to 42% with esomeprazole, a difference that was 
statistically significant (P , 0.001). At 0–12 hours postdose, 
the mean percentage of time with pH . 4 for dexlansoprazole 
and esomeprazole was 56% and 53%, respectively, and the 
  difference was not statistically significant.
Over the 24-hour postdose period, the average of mean 
intragastric pH for dexlansoprazole was 4.3 compared with 3.7 
for esomeprazole and the difference was statistically significant 
(P , 0.001, Figure 3). Likewise, .12–24 hours postdose, the 
average of mean intragastric pH was 4.5 for   dexlansoprazole 
compared with 3.5 for esomeprazole and the difference was 
statistically significant (P , 0.001). At 0–12 hours postdose, 
the average of mean intragastric pH for dexlansoprazole was 
4.2 compared with 3.9 for esomeprazole, and the difference 
was not statistically significant.
Pharmacokinetics
The mean plasma concentration-time curves for dexlansopra-
zole and esomeprazole in our study were generally similar to 
that reported in the literature.2,13–15 Following administration 
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Figure 1 Mean intragastric pH from 0 to 24 hours postdose after single oral doses of dexlansoprazole modified-release 60 mg (n = 43) and esomeprazole 40 mg (n = 44) 
delayed-release capsules.
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Figure 2 Mean percentage of time with intragastric pH . 4.0 at 0–24 hours, 
0–12 hours, and .12–24 hours after single oral doses of dexlansoprazole modified-
release 60 mg and esomeprazole 40 mg delayed-release capsules (n = 43). Only 
subjects who had valid pharmacodynamic parameters estimated for both periods 
were included in the pharmacodynamic analyses for that parameter.
Notes: *P # 0.05; **P , 0.01; ***P , 0.001.
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Figure 3 Mean intragastric pH at 0–24 hours, 0–12 hours, and .12–24 hours after 
single oral doses of dexlansoprazole modified-release 60 mg and esomeprazole 40 mg 
delayed-release capsules (n = 43). Only subjects who had valid pharmacodynamic 
parameters  estimated  for  both  periods  were  included  in  the  pharmacodynamic 
analyses for that parameter.
Notes: *P # 0.05; **P , 0.01; ***P , 0.001.
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of a single dose of dexlansoprazole modified-release 60 mg, 
the mean plasma concentration-time curve displayed two 
peaks at approximately 2 and 5 hours postdose, which are 
representative of the dual delayed-release characteristics of 
the dexlansoprazole modified-release capsule; in addition, 
plasma concentrations were generally detectable throughout 
the 24-hour postdose interval. For esomeprazole, the median 
Tmax occurred at approximately two hours after   dosing, 
and plasma concentrations rapidly decreased thereafter 
(Figure 4). Concentrations of dexlansoprazole were detect-
able in the plasma of all subjects (100%) at 12 hours postdose, 
in 38 of 43 subjects (88%) at 16 hours postdose, and 27 of 
43 subjects (63%) at 24 hours postdose. In contrast, esome-
prazole was detected in the plasma of 35 of 44 subjects (80%) 
at 12 hours postdose, 17 of 44 subjects (39%) at 16 hours 
postdose, and four of 44 subjects (9%) at 24 hours postdose. 
Plasma pharmacokinetic parameters for dexlansoprazole and 
esomeprazole are shown in Table 1.
Effect of CYP2C19 status on 
pharmacodynamics and pharmacokinetics
Administration of a proton pump inhibitor with CYP2C19-
dependent metabolism may result in higher plasma concentra-
tions in subjects who are CYP2C19 poor metabolizers. Two 
of the 44 enrolled subjects were determined to be CYP2C19 
poor metabolizers. Both subjects had AUC values that were 
substantially higher than the overall means for dexlansopra-
zole and esomeprazole. Data for these subjects were included 
in the pharmacodynamic analyses and pharmacokinetic 
summary because this was a crossover study where subjects 
received both treatment regimens, and subject metabolizer 
status was not expected to affect the overall conclusions of 
the study. To confirm this assumption, an analysis of   variance 
model that was similar to the analysis for the complete data 
was fitted to the pharmacodynamic data, excluding the data 
from the two poor metabolizer subjects. Exclusion of the 
pharmacodynamic data from the poor metabolizers did not 
alter the statistical results obtained from the complete data 
set. Additional descriptive statistics were calculated for the 
pharmacodynamic and pharmacokinetic parameter data, 
excluding the data from the poor metabolizers, and indicated 
that inclusion of data from the poor metabolizers did not 
affect the overall pharmacodynamic or pharmacokinetic 
conclusions of the study (data on file at Takeda).
Safety
The incidence of treatment-emergent adverse events was 
21% (nine of 43 subjects) and 14% (six of 44 subjects) after 
single-dose administration of dexlansoprazole modified-
release and esomeprazole, respectively. All of the adverse 
events were rated mild or moderate in severity and only one 
adverse event (nausea) was considered related to the study 
drug (dexlansoprazole modified-release) by the investiga-
tor. The most common adverse events reported by at least 
two subjects with dexlansoprazole modified-release were 
headache (four of 43 subjects, 9%), flatulence (two of 
43 subjects, 5%), and joint injury (two of 43 subjects, 5%). 
No adverse event was reported by two or more subjects with 
esomeprazole. There were no serious adverse events, deaths, 
or premature study discontinuations as a result of an adverse 
event. No clinically meaningful changes in clinical laboratory 
Table 1 Summary of plasma pharmacokinetic parameters for 
dexlansoprazole  and  esomeprazole  after  single  oral  doses  of 
dexlansoprazole MR 60 mg and esomeprazole 40 mg
Pharmacokinetic  
parameter (unit)
Treatment mean ± SD
Dexlansoprazole  
MR 60 mg
Esomeprazole  
40 mg
n (N = 43) n (N = 44)
AUCt (ng ⋅ hour/mL) 43 5666 ± 4763.3 44 1877 ± 1265.8
AUC∞ (ng ⋅ hour/mL) 32 6841 ± 5787.7 41 1984 ± 1254.3
Cmax (ng/mL) 43 1078 ± 581.5 44 748 ± 444.6
Tmax (hour)a 43 5.00 (1.0, 12.0) 44 2.00 (1.0, 10.0)
T1/2 (hour) 32 2.83 ± 2.174 41 1.35 ± 0.437
CL/F (L/hour) 32 13.83 ± 9.433 41 28.68 ± 17.364
Vz/F (L) 32 52.70 ± 59.859 41 51.29 ± 31.140
Note: aTmax values presented are median (minimum, maximum).
Abbreviations:  AUCt,  area  under  the  plasma  concentration-time  curve  from 
time 0 to the time of last quantifiable concentration; AUC∞, area under the plasma 
concentration-time  curve  from  time  0  to  infinity;  CL/F,  oral  clearance;  Cmax, 
maximum  observed  plasma  concentration;  MR,  modified-release;  N,  number  of 
subjects; n, number of subjects for whom parameter could be calculated; T1/2, half-
life; Tmax, time to reach Cmax; Vz/F, apparent volume of distribution.
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Figure  4  Mean  plasma  concentration-time  curves  of  dexlansoprazole  and 
esomeprazole  after  single  oral  doses  of  dexlansoprazole  modified-release  60  mg 
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values, physical examination findings, vital signs, or 12-lead 
electrocardiograms were reported over the course of study.
Discussion
Proton pump inhibitors are the drugs of choice for the 
healing of erosive esophagitis, maintenance of healed 
erosive esophagitis, and sustained resolution of symptomatic, 
nonerosive reflux disease. Limitations to the use of proton 
pump inhibitors on a once-daily basis have been a delayed 
onset of action, incomplete acid suppression over the 24-hour 
postdose interval, and the need for ingestion before a meal 
to achieve maximal efficacy.1,3 To date, attempts to overcome 
these issues have included the development of isomeric 
proton pump inhibitors with stereoselective metabolism (ie, 
dexlansoprazole [the R-enantiomer of lansoprazole] and 
esomeprazole [the S-enantiomer of omeprazole]) and altera-
tions in drug delivery to prolong the inhibition of gastric 
acid secretion.3 The dexlansoprazole DDR technology is 
designed to provide an initial drug release in the proximal 
small intestine followed by another drug release at more distal 
regions of the small intestine several hours later. As a result, 
dexlansoprazole modified-release produces a dual-peaked 
pharmacokinetic profile that prolongs the plasma concentra-
tion-time profile of dexlansoprazole.2 Unlike esomeprazole, 
which should be taken one hour prior to a meal,5 dexlansopra-
zole modified-release can be taken without regard to food.4 
The aim of this study was to evaluate the pharmacodynamic 
effects of single doses of dexlansoprazole modified-release 
60 mg and esomeprazole 40 mg on 24-hour intragastric pH in 
healthy subjects. The dosage strengths chosen for this study 
were the highest approved for healing of erosive esophagitis 
(60 mg for dexlansoprazole modified-release and 40 mg for 
esomeprazole).
The measurement of intragastric pH is a well accepted 
method for the assessment of the pharmacodynamic effects 
of a proton pump inhibitor.16–18 The present study is the first 
head-to-head comparison of the pharmacodynamic effects for 
a 24-hour period following single doses of dexlansoprazole 
modified-release and esomeprazole in healthy subjects, 
utilizing doses that are recommended for healing of erosive 
esophagitis.
The results of this study indicate that the DDR formulation 
technology of dexlansoprazole modified-release leads to an 
extended duration of gastric acid control on day 1 compared 
with the delayed-release formulation of esomeprazole. After 
a morning dose of each study drug, the extended duration in 
pharmacodynamic activity after dexlansoprazole modified-
release was demonstrated 0–24 hours postdose, mainly due to 
the significant differences observed during the .12–24 hours 
postdose interval relative to esomeprazole. The two proton 
pump inhibitors had comparable pharmacodynamic activity 
0–12 hours postdose.
Overall, the pharmacodynamic profiles in our study were 
similar to those observed in other published reports.2,9 The 
primary pharmacodynamic parameter, mean percentage of 
time with intragastric pH . 4 from time 0–24 hours postdose, 
was 58% for dexlansoprazole versus 48% for esomeprazole 
(Figure 2). The literature reported that percentage of time 
with intragastric pH . 4 from time 0–24 hours after the same 
doses were approximately 60% for dexlansoprazole modi-
fied-release2 and 54% and 52% for esomeprazole.10,12
A strength of this study is its randomized, crossover design, 
with each subject acting as his/her own control. A   limitation 
is the single-dose design, preventing extrapolation of the 
results to a multiple-dose regimen. The study population of 
healthy volunteers does not allow for assessment of clinical 
efficacy, and no clinical significance is intended or implied. 
Nevertheless, the comparison of two proton pump inhibitor 
enantiomers with different formulation characteristics is of 
pharmacological interest. Although there are extensive data 
available detailing the multiple-dose pharmacodynamics 
and pharmacokinetics of proton pump inhibitors, this is 
the first clinical study reported in the literature to provide a 
comparison of the pharmacodynamics of dexlansoprazole 
modified-release and esomeprazole after a single dose in a 
well controlled crossover study.
In conclusion, a single dose of dexlansoprazole modified-
release 60 mg provided statistically significantly greater 
pH control for the entire 24-hour postdose interval when 
compared with a single dose of esomeprazole 40 mg. This 
observed difference was mainly due to the statistically sig-
nificant greater pH control from dexlansoprazole modified-
release over the .12–24-hour postdose interval as compared 
with esomeprazole. The two proton pump inhibitors had com-
parable pharmacodynamic activity at 0–12 hours postdose.
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